JP Morgan Chase’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $59.5M | Sell |
837,452
-480,149
| -36% | -$24.8M | ﹤0.01% | 1351 |
|
|
2026
Q1 | $63.5M | Buy |
1,317,601
+303,717
| +30% | +$14.2M | ﹤0.01% | 1237 |
|
|
2025
Q4 | $29.9M | Sell |
1,013,884
-373,157
| -27% | -$10.1M | ﹤0.01% | 1713 |
|
|
2025
Q3 | $35.8M | Sell |
1,387,041
-874,752
| -39% | -$24.4M | ﹤0.01% | 1636 |
|
|
2025
Q2 | $62.4M | Buy |
2,261,793
+1,402,737
| +163% | +$36.9M | ﹤0.01% | 1194 |
|
|
2025
Q1 | $24.4M | Buy |
859,056
+335,879
| +64% | +$11.9M | ﹤0.01% | 1763 |
|
|
2024
Q4 | $21.8M | Sell |
523,177
-1,703,867
| -77% | -$81.4M | ﹤0.01% | 1968 |
|
|
2024
Q3 | $149M | Buy |
2,227,044
+470,336
| +27% | +$43.2M | 0.01% | 796 |
|
|
2024
Q2 | $209M | Buy |
1,756,708
+315,268
| +22% | +$39.9M | 0.02% | 638 |
|
|
2024
Q1 | $154M | Sell |
1,441,440
-1,087,231
| -43% | -$110M | 0.01% | 749 |
|
|
2023
Q4 | $251M | Sell |
2,528,671
-52,885
| -2% | -$4.45M | 0.02% | 550 |
|
|
2023
Q3 | $267M | Buy |
2,581,556
+166,182
| +7% | +$18.5M | 0.03% | 466 |
|
|
2023
Q2 | $293M | Buy |
2,415,374
+531,790
| +28% | +$70.9M | 0.03% | 454 |
|
|
2023
Q1 | $289M | Buy |
1,883,584
+1,089,003
| +137% | +$180M | 0.04% | 427 |
|
|
2022
Q4 | $143M | Buy |
794,581
+103,009
| +15% | +$16.8M | 0.02% | 633 |
|
|
2022
Q3 | $81.8M | Sell |
691,572
-446,785
| -39% | -$67.8M | 0.01% | 806 |
|
|
2022
Q2 | $163M | Buy |
1,138,357
+75,202
| +7% | +$10.7M | 0.02% | 569 |
|
|
2022
Q1 | $183M | Sell |
1,063,155
-5,514
| -0.5% | -$928K | 0.02% | 588 |
|
|
2021
Q4 | $271M | Sell |
1,068,669
-209,082
| -16% | -$61.1M | 0.03% | 490 |
|
|
2021
Q3 | $492M | Sell |
1,277,751
-210,229
| -14% | -$77.5M | 0.06% | 314 |
|
|
2021
Q2 | $350M | Sell |
1,487,980
-803,573
| -35% | -$144M | 0.04% | 438 |
|
|
2021
Q1 | $300M | Sell |
2,291,553
-333,959
| -13% | -$48.4M | 0.04% | 454 |
|
|
2020
Q4 | $274M | Buy |
2,625,512
+376,621
| +17% | +$38.1M | 0.04% | 441 |
|
|
2020
Q3 | $159M | Buy |
2,248,891
+568,761
| +34% | +$39.7M | 0.03% | 542 |
|
|
2020
Q2 | $108M | Sell |
1,680,130
-757,315
| -31% | -$41.5M | 0.02% | 628 |
|
|
2020
Q1 | $73M | Buy |
2,437,445
+104,567
| +4% | +$2.41M | 0.02% | 677 |
|
|
2019
Q4 | $45.6M | Buy |
2,332,878
+266,191
| +13% | +$4.72M | 0.01% | 1016 |
|
|
2019
Q3 | $32.9M | Sell |
2,066,687
-1,045,343
| -34% | -$15.4M | 0.01% | 1214 |
|
|
2019
Q2 | $44.6M | Buy |
3,112,030
+1,675,790
| +117% | +$36M | 0.01% | 1029 |
|
|
2019
Q1 | $29.2M | Sell |
1,436,240
-46,970
| -3% | -$872K | 0.01% | 1274 |
|
|
2018
Q4 | $22.6M | Buy |
+1,483,210
| New | +$24.4M | 0.01% | 1395 |
|
Other funds holding MRNA
TP
JP Morgan Chase's MRNA Position: Q2 2026 in Review
JP Morgan Chase reduced its Moderna (MRNA) stake by 36% in Q2 2026, selling an estimated $24.8M and leaving 837,452 shares worth $59.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1351.
JP Morgan Chase first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $492M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- JP Morgan Chase held 837,452 shares of Moderna worth $59.5M as of Q2 2026.
- JP Morgan Chase sold 480,149 Moderna shares in Q2 2026, an estimated $24.8M.
- Moderna made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1351 holding.
- JP Morgan Chase first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
- JP Morgan Chase's Moderna position peaked at $492M in Q3 2021.
- 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.